Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
Meletios A. Dimopoulos, MD, discussed the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
Transcription:
We have a new triplet—selinexor (Xpovio), bortezomib (Velcade), and dexamethasone—which could be administered for patients who have received 1 to 3 prior lines of therapy. It could be 1 of the treatments that could be used for patients who have been exposed and progress on lenalidomide (Revlimid) maintenance or continuous treatment. I believe it is an additional combination for the treatment of myeloma patients.
It gives another combination. For example, whenever we have patients who progressed on lenalidomide, often times we use a pomalidomide-based regimen. In this case, we could change completely the mode of action, move to a combination that is not including anemic, and then maybe use pomalidomide (Pomalyst) later on.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
